Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | ||||||
{[ item.p_purity ]} | {[ item.pr_size ]} | Inquiry |
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price) ]} |
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price) ]} | {[ item.pr_usastock ]} | in stock Inquiry - | {[ item.pr_chinastock ]} | {[ item.pr_remark ]} in stock Inquiry - | Login | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
CAS No. : | 61903-11-5 | MDL No. : | MFCD00674492 |
Formula : | C7H14N2O | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | TWJPZMYNUBAUGA-UHFFFAOYSA-N |
M.W : | 142.20 | Pubchem ID : | 4186202 |
Synonyms : |
|
Num. heavy atoms : | 10 |
Num. arom. heavy atoms : | 0 |
Fraction Csp3 : | 0.86 |
Num. rotatable bonds : | 1 |
Num. H-bond acceptors : | 2.0 |
Num. H-bond donors : | 1.0 |
Molar Refractivity : | 47.38 |
TPSA : | 32.34 Ų |
GI absorption : | Low |
BBB permeant : | No |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -7.58 cm/s |
Log Po/w (iLOGP) : | 1.72 |
Log Po/w (XLOGP3) : | -0.58 |
Log Po/w (WLOGP) : | -0.93 |
Log Po/w (MLOGP) : | -0.05 |
Log Po/w (SILICOS-IT) : | 0.59 |
Consensus Log Po/w : | 0.15 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 1.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -0.29 |
Solubility : | 72.9 mg/ml ; 0.513 mol/l |
Class : | Very soluble |
Log S (Ali) : | 0.37 |
Solubility : | 335.0 mg/ml ; 2.35 mol/l |
Class : | Highly soluble |
Log S (SILICOS-IT) : | -0.97 |
Solubility : | 15.3 mg/ml ; 0.108 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 1.52 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H319 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
at 200℃; for 0.1h;Microwave; | To a solution of 1 ([1-(6-Chloro-pyrimidin-4-yl)-1H-[1, 2,4] TRIAZOL-3-YL]-PHENYL-AMINE, (27 mg, 0,1 mmol) was added N-acetyl-homopeparazine (150MG, 1.05 mmol). The reaction was heated in a microwave at 200 C over 6min. The reaction was cooled to room temperature and was diluted with ethyl acetate. The mixture was washed with water several times and the organic layer was concentrated, dissolved in DMSO. The material was purified by P-HPLC to give 25 mg of desired product as TFA salt. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
90% | With N-ethyl-N,N-diisopropylamine; at 90℃; for 6h; | 4.67 g (30 mmol) 3-chloro-4-fluoro-benzonitrile and 4.27 g (30 mmol) N-1-acetyl-[1,4]diazepan are stirred in 5.0 ml DIPEA for 6 hours at 90 C. Then the mixture is evaporated down i. vac. and the residue is dissolved in dichloromethane. The organic phase is washed twice with water, dried over sodium sulphate and evaporated down i. vac. The residue is further reacted without any more purification. Yield: 7.50 g (90%) Rf value: 0.20 (silica gel; dichloromethane/ethanol=50:1) |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With potassium carbonate; In DMF (N,N-dimethyl-formamide); at 80℃; for 0.25h; | A solution of 8 (0.035g, 0.091mmol), N-acetyl-homopiperizine (0.025g, 0.181mmol), excess potassium carbonate in DMF was heated at 80C resulting in a color change after 5 minutes. LC/MS and TLC indicated conversion to tosyl protected product after 15 minutes. 1 ml of 6N NaOH and 1ml of methanol were added to the reaction resulting in the immediate removal the tosyl group by LC/MS (M+1=337). The reaction was partitioned between EtOAc/Et2O and extracted. The crude product was purified by preparative HPLC giving 9 (0.022g) as a clear oil in 73% yield. [00187] NMR : MeOD 2.0 bs (2H), 2.1 s (3H), 3.6 m (2H), 3.8-4.3 bm (6H), 7.1 d (1H), 7.3 m (1H), 8.2 d (1H), 8.35 m (2H), 8.65 d (1H). LC/MS (M+1) =337 |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
40% | Lithium aluminum hydride (38.2 ml, 38.19 mmol) was added to <strong>[61903-11-5]1-(1,4-diazepan-1-yl)ethanone</strong> (1.697 g, 11.93 mmol) in THF (59.7 ml) at 0 C. under nitrogen. The resulting solution was stirred at ambient temperature for 1 h and then at 60 C. for 1 h. The cooled reaction mixture was poured onto ice (500 mL), acidified with HCl (2M aqueous solution) and purified by ion exchange chromatography, using an SCX column. The desired product was eluted from the column using 7M NH3/MeOH and evaporated to dryness to afford 1-ethyl-1,4-diazepane (0.610 g, 40%) as a yellow liquid. This was used directly with no further purification. 1H NMR (399.9 MHz, CDCl3) delta 1.07 (3H, t), 1.74-1.80 (2H, m), 2.58 (2H, q), 2.64-2.70 (4H, m), 2.89-2.95 (4H, m). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
Example 35~(4-Acetyl-[l, 4]dia?epan-l-yl)-pentanoic acid (5-thiophen-2-yl-lH-pyra?ol- 3-yl)-amideBromovaleryl chloride (1.62 niL, 12.12 mmol) was dissolved in DMA (50 mL). To this, a solution of 5-thiophen-2-yl-2H-pyrazol-3-ylamine (2 g, 12.12 mmol) and DIEA (2.1 mL, 12.12 mmol) was added portionwise at O0C. The reaction mixture was left stirring 1 hour at 0C and then for 2 hours at room temperature. After a total of 3 hours, PS-Trisamine (1 g, ~4mmol/g) was added to the mixture and left stirring for 2 hours. Then, 7V-acetylhomopiperazine (4.3 g, 30.3 mmol) was added and the mixture was left stirring at room temperature for a further 60 hours. After DMA evaporation under reduced pressure, water was added (50 mL) and this was extracted with ethyl acetate (3x 30 mL). The aqueous layer was basified with solid NaOH and extracted with ethyl acetate at pH=10 and then again at pH=l 1. All the organic phases were reunited, dried and evaporated. The residue was purified by silica chromatography eluting with a gradient of ethyl acetate/metlianol 9: 1 up to ethyl acetate/methanol 8:2, to give the title compound as yellowish oil (800 mg, 17%).Cj9H27N5O2S Mass (calculated) [389.52]; (found) [M+H+]=390.11NMR (400 MHz, CDCl3): 1.52 (2H, m); 1.77 (2H, m); 1.82 (2H, m); 2.13+2.09 (3H, s); 2.44 (2H, m);2.56 (2H, m); 2.62 (IH, m); 2.76-2.70 (3H, m); 3.51 (2H5 m); 3.61 (IH, m); 3.64 (IH, m); 6.48 (IH, s); 6.56 (IH, s); 7.05-7.02 (2H, m); 6.9-7.26 (2H, m); 8.94 (IH, s); 9.53 (IH, s). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With sodium iodide; In ISOPROPYLAMIDE; at 60℃; | The reaction was left stirring for Ih at O0C and then l-[l ,4]diazepan-l-yl- ethanone (0.310 mL, 2.35 mmol) and NaI (0.94mmol5 1 eq) were added.The reaction mixture was heated at 6O0C until LC-MS analysis showed complete conversion of the bromo-intermediate, at which point the reaction was cooled down and the solvent was removed under reduced pressure. The residue was dissolved in DCM (2 mL) and washed with saturated Na2CO3 solution.The organic phase was concentrated under reduced pressure and half of the crude was purified by SiO2 column (gradient from 100% DCM to DCM-NH3MeOH 2N solution 8 :2). The fractions containing the title compound were collected (35 mg).023H33NsO3Mass (calculated) [427]; (found) [M-H+] -428LC Rt = 1.61 , 96% (10 min method)1H-NMR (400 MHz, dmso-d6): 1.24-1.29 (2H. m); 1.36-1.44 (2H5 m); 1.54- 1.58 (2H5 m); 1.62-1.76 (2H, m); 1. 94-1.96 (3H5 m); 2.25-2.28 (2H, m); 2.35-2.41 (2H, m); 2.51 -2.54 (2H5 m); 2.60-2.62 (IH5 m); 3.38-3.44 (5H5 m); 3.77 (3H5 s); 6.73 (IH5 s); 6.98 (2H5 d, J=S.8 Hz); 7.61 (2H, d5 J=S.8); 10.32 (IH, s) |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
54% | With triethylamine; In dichloromethane; at 20 - 50℃; for 40h; | e) 5-[5-(4-Acetyl-[l,4]diazepan-l-yl)-2-methyl-pentanoylamino]-3-(4- methoxy-phenyl)-pyrazole-l -carboxylic acid tert-butyl ester <n="141"/>5-(5-Bromo-2-methyl-pentanoylamino)-3-(4-methoxy-phenyl)-pyrazole-l - carboxylic acid tert-butyl ester (280.0 mg, 0.6 mmol, 1.0 eq) was dissolved in DCM (3 mL). Triethylamine (80 muL, 0.6 mmol, 1.0 eq) and l -[l ,4]~diazepan-l-yl-ethanone (158 muL, 170.0 mg, 1.2 mmol, 2.0 eq) were added and the mixture was stirred at room temperature for 24 hours, then at 5O0C for 16 hours. NaHCO3 saturated solution was added and the organic layer separated and collected. Evaporation of the solvent gave a crude product purified using SiO2 column (elution DCM, DCMiMeOH 99: 1 to 96:4) obtaining the title product (181.3 mg, yield 54%).C28H41N5O5Mass (calculated) [527]; (found) [M-H+] =528LC Rt = 1.63 min, 100% (5 min method).IH-NMR (dmso-d6): 1.13 (3H, d, J= 6.4 Hz); 1.33-1.50 (4H, m); 1.62 (9H, s); 1.65-1.81 (2H, m); 1.96 (3H, s); 2.34-2.44 (IH, m); 2.52-2.67 (3H, m); 2.98-3.13 (3H, m); 3.40-3.46 (4H, m); 3.80 (3H, s); 7.01 (2H, br d, J= 8.8 Hz); 7.06 (IH5 s); 7.79 (2H, br d, J= 8.8 Hz); 10.07 (IH, s). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
54% | With triethylamine; In butanone; for 48h;Heating / reflux; | c) 5-(4-Acetyl-[l ,4]diazepan-l-yl)-2-methyl-pentanoic acid [5-(4-chloro- phenyl)-2H-pyrazol-3-yl] -amide l-[l ,4]Diazepan- l -yl-ethanone (1.4 niL, 10.8 mmol, 1.2 eq) was added to a solution of 5-(5-bromo-2-methyl-pentanoylamino)-3-(4-chloro-phenyl)-pyrazole-l - carboxylic acid tert-butyl ester (3.3 g, 9.0 mmol. 1.0 eq) and triethylamine (1.25 mL, 9.0 mmol, 1.0 eq) in 2-butanone (15 mL) and the mixture was stirred at reflux for 48 hours. After solvent removal, DCM (5 mL) and TFA (3 mL) were added and the mixture was stirred at room temperature for 3 hours. DCM and TFA were evaporated under reduced pressure and the crude was treated with a solution of saturated Na2CO3 and extracted with EtOAc. The crude was purified through SiO2 column (gradient elution from 100% DCM to DCM-NH3 in MeOH 2N 92:8).1.7 g (yield 44%) of the title product was recovered.C22H30C1N5O2Mass (calculated) [431]; (found) [M^H+] =432.LC Rt = 1.80 min, 90% (10 min method)IH-NMR (CDC13): 1.14-1.21 (3H, d, J = 6.58 Hz); 1.36-1.53 (IH5 m); 1.53- 2.0 (6FI, m); 2.1 (3H, s); 2.48-3.07 (6FL m); 3.39-3.77 (4H, m); 6.93 (lH,s); 7.49 (2H, d, J= 8.0 Hz); 7.71 (2H,d, J= 8.0 Hz); 10.40 (IH, s); 12.87 (IH, s). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
82% | With sodium t-butanolate;tris-(dibenzylideneacetone)dipalladium(0); 2,2'-bis-(diphenylphosphino)-1,1'-binaphthyl; In toluene; at 20 - 80℃; | a) 1 -Acetyl-4-(4-bromophenyl)-[1 ,4]diazepan <n="64"/>To a solution of 1 ,4-dibromobenzene (3.30 g, 14 mmol) in toluene (44 ml_) under Ar-atmosphere, sodium te/t-butoxide (1.88 g, 19.60 mol), BINAP (0.17 g, 0.28 mmol), Pd2(dba)3 (0.13 g, 0.14 mmol) and 1-acetylhomopiperazine (2 g, 14 mmol) were added at room temperature. The reaction mixture was heated at 80 C overnight. The resulting mixture was cooled, diluted with MeOH and filtered over CeI ite. The filtrate was concentrated to dryness. The crude product obtained was chromatographed over silica gel using Hexane/EtOAc mixtures of increasing polarity as eluent, to afford 3.42 g of the desired compound (82% yield). LC-MS (method 1 ): tR = 7.08 min; m/z = 299 (MH+). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
63% | With N-ethyl-N,N-diisopropylamine; In butan-1-ol; at 120℃; for 18h; | a) beta-Ibeta^-Acetylli^ldiazepan-i-yOpyridin-S-yll^-chloro-theta^tetrahydropyran- 2-yl)-9H-purine To a solution of reference example 2 (0.30 g, 0.89 mmol) and DIEA (0.47 ml_, 2.69 mmol) in n-BuOH (25 ml_), /V-acetylhomopiperazine (0.51 g, 3.59 mmol) was added. The mixture was heated for 18 h at 120 C, it was allowed to cool, and was concentrated to dryness. The crude product obtained was chromatographed over silica gel using hexane/EtOAc mixtures of increasing polarity as eluent, to afford 0.26 g of the desired compound (63% yield).LC-MS (method 1 ): tR = 7.24 min; m/z = 456 (MH+). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
53.6% | With potassium carbonate; In water; at 95℃; for 6h; | Step 1: Synthesis of 1- (3-Methyl-4-Nitrophenyl)-[1,4]Diazepane (1): Fluoronitrobenzene (9.1 g, 0.0586 mol) is dissolved in water (50 ml) and then potassium carbonate (9.7 9, 0.0703 mol) and 1-acetyl-[1,4]diazepane (10 g, 0.0703 mol) are added. The medium is heated at 95 C. for 6 hours, and an orange-coloured solution is obtained. The medium is then cooled to room temperature, and an orange-coloured sticky paste then appears. The maximum amount of water is removed from the reaction medium. Isopropanol is then added to the paste until a yellow solid precipitates. The medium is filtered and, after drying in a vacuum oven at 45 C., a yellow powder is obtained which corresponds to 1-(3-methyl-4-nitrophenyl)-[1,4]diazapane (1). (8.7 g; Yield=53.6%) |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
62% | With N-ethyl-N,N-diisopropylamine; sodium iodide; In N,N-dimethyl-formamide; at 50℃; for 18h;Product distribution / selectivity; | iii) 5-(4-acetyl-[1,4]diazepan-1-yl)-pentanoic acid [5-(4-methoxy-phenyl)-1H-pyrazol-3-yl]-amide5-bromo-pentanoic acid [5-(4-methoxy-phenyl)-1H-pyrazol-3-yl]amide (1.5 g, 4.26 mmol) was dissolved in DMF (15 mL), and sodium iodide (0.64 g, 4.26 mmol) was added followed by N-acetylhomopiperazine (0.56 mL, 4.26 mmol) and diisopropylethylamine (0.74 mL, 4.26 mmol). The reaction was stirred under N2 at 50 C. for 18 hrs. Upon reaction completion (as monitored by LCMS), the solvent was removed at reduced pressure and the resulting oily residue was dissolved in DCM (20 mL), washed with sat. Na2CO3 (2×20 mL) and sat. NaCl (2×20 mL), and dried over Na2SO4. Upon solvent removal, 1.7 g of crude product as a thick oil were obtained. The product was purified by SiO2 chromatography (10 g cartridge-flash SI II from IST) employing DCM and DCM:MeOH 9:1 to yield 0.92 g of pure product and 0.52 g of less pure product. A second purification of the impure fractions using a 5 g SiO2 cartridge was performed using the same eluent. Overall, 1.09 g of 5-(4-acetyl-[1,4]diazepan-1-yl)-pentanoic acid [5-(4-methoxy-phenyl)-1H-pyrazol-3-yl]-amide were obtained (2.64 mmol, 62% yield) as a thick light yellow oil. MS (ES+): 414.26 (M+H)+. |
62% | With N-ethyl-N,N-diisopropylamine; sodium iodide; In N,N-dimethyl-formamide; at 50℃; for 18h;Product distribution / selectivity; | To a solution of 5-(4-methoxyphenyl)-lH-pyrazol-3-ylamine (12 g, 62.8 mmol) and 7V,7V-diisopropylethylamine (10.96 mL, 62.8 mmol) in dry N,N- <n="63"/>dimethylformamide (150 mL) at -10 0C was added a solution of 5-bromovaleryl chloride (8.4 mL, 62.8 mmol) in dry 7V,7V-dimethylformamide (50 mL) slowly (-40 min) and the reaction mixture was allowed to stir at -10 to 0 0C for 8 hrs. Sodium iodide (9.44 g, 62.8 mmol) was added at 0 0C and followed by N-acetylhomopiperazine (8.24 mL, 62.8 mmol) and 7V,7V-diisopropylethylamine (10.96 mL, 62.8 mmol) and the reaction mixture was allowed to stir at 50 0C for 18 hrs. The solvent was removed in vacuo. The residue was dissolved in methylene chloride (500 mL) and saturated aqueous sodium bicarbonate (500 mL) and the mixture was stirred at room temperature for 30 minutes. The organic layer was separated, dried over sodium sulfate, and the solvent was removed in vacuo to provide 25.8 g (99%) of 5-(4-acetyl-l,4-diazepan-l-yl)-N-(5-(4-methoxyphenyl)-lH- pyrazol-3-yl)pentanamide as a thick light yellow oil (crude).[00228] Then to a solution of the crude 5-(4-acetyl-l,4-diazepan-l-yl)-N-(5-(4- methoxyphenyl)-lH-pyrazol-3-yl)pentanamide (as a free base) in methylene chloride (270 mL) at room temperature was added hydrogen chloride (65 mL, 1.0 M in ethyl ether) slowly. The resulting suspension was allowed to stir at room temperature for 1 hour. The solvent was removed in vacuo to afford 33 g as a yellow foam, mono hydrochloride salt. The foam was dissolved in solvents (330 mL, acetonitrile : methanol = 33 : 1) at 60-70 0C and a crystal seed was added. The mixture was slowly cooled down to the room temperature and allowed to stir at room temperature for 15 hours. The resulting precipitate was filtered and dried to give 20.5 g (72%) of the title compound as a white crystal, mono hydrochloride salt. MS [M-H]" m/z 412.3; mp. 132-133 0C. 1H NMR (400 MHz, DMSO-fc) delta 10.6-10.8 (br, IH), 10.45 (s, IH), 7.64 (d, J = 8 Hz, 2H), 7.00 (d, J = 8 Hz, 2H), 6.74 (s, H), 4.00(m, IH), 3.77 (s, 3H), 3.4-3.6 (m, 6H), 2.9-3.0 (m, 5H), 2.34 (m, 2H), 2.0 (s, 3H), 1.65-1.70 (m, 2H), 1.55-1.65 (m, 2H).;5-bromo-pentanoic acid [5-(4-methoxy-phenyl)-lH-pyrazol-3-yl]amide(1.5 g, 4.26 mmol) was dissolved in DMF (15 mL), and sodium iodide (0.64 g, 4.26 mmol) was added followed by N-acetylhomopiperazine (0.56 mL, 4.26 mmol) and diisopropylethylamine (0.74 mL, 4.26 mmol). The reaction was stirred under N2 at 50 0C for 18 hrs. Upon reaction completion (as monitored by LCMS), the solvent was removed at reduced pressure and the resulting oily residue was dissolved in DCM (20 mL), washed with sat. Na2CO3 (2 x 20 mL) and sat. NaCl (2 x 20 mL), and dried over Na2SO4. Upon solvent removal, 1.7 g of crude product as a thick oil were obtained. The product was purified by SiO2 chromatography (1O g cartridge-flash SI II from 1ST) employing DCM and DCM:MeOH 9: 1 to yield 0.92 g of pure product and 0.52 g of less pure product. A second purification of the impure fractions using a 5 g SiO2 cartridge was performed using the same eluent. Overall, 1.09 g of 5-(4-acetyl-[l,4]diazepan-l-yl)-pentanoic acid <n="67"/>[5-(4-methoxy-phenyl)-lH-pyrazol-3-yl]-amide were obtained (2.64 mmol, 62% yield) as a thick light yellow oil. MS (ES+): 414.26 (M+H)+. |
Bromopyrazole is mixed with K2CO3 and KI in 10 volumes of acetone at room temperature and N-acetylhomopiperazine was added over 1 hr. The reaction mixture was stirred until the reaction was complete. The mixture was filtered, removing the inorganics, washed with acetone and distilled to 2 volumes. The freebase was extracted into methyl THF/ EtOH and washed with NaCl and NaHCO3. The solvent was replaced with EtOH, a strength of the solution was determined, and 0.93 eq of HCl based on the available freebase was added to a mixture of acetone, ethanol and water. Careful <n="65"/>monitoring of the pH yielded crystalline product in a 70% overall yield and the desired form 1.;To a cylindrical, jacketed 3 L reactor equipped with nitrogen inerting, agitator, condenser/distillation head, and temperature control, 5-bromo-pentanoic acid [5- (4-methoxy-phenyl)-lH-pyrazol-3-yl]amide (0.15 kg, 0.426 mol), potassium carbonate (0.059 kg, 0.426 mol), potassium iodide (0.071 kg, 0.426 mol), and acetone (1.18 kg, 1.5 L) were added (at 20 0C) to form a white mixture. The mixture was stirred (235 rpm) at 25-30 0C for a minimum of 15 min. N-acetylhomopiperazine (0.062 kg, 0.057 L, 0.434 mol) was added via addition funnel to the reactor over a minimum of 45 min., maintaining the temperature in the range of 25-30 0C. The addition funnel was rinsed with 0.05 L acetone. A white mixture persisted. The mixture was stirred (235 rpm) in the range of 25-30 0C for a minimum of 16 h, forming a white/yellow mixture. The reaction progress was monitored by HPLC and was considered complete when there was < 2% of the starting material (bromopyrazole) and < 2% of the iodopyrazole present. [00240] The reactor contents were cooled to 5-15 0C over a minimum of 15 min with agitation (295 rpm) to form a white/yellow mixture that was then stirred for a <n="68"/>minimum of 1 h. To remove inorganics, the mixture was then filtered on a Buchner funnel with filter paper using house vacuum for 1.5 min. The cake was washed twice with acetone (total of 0.24 kg, 0.30 L) at 5-15 0C. The wash was combined with the mother liquor from the prior filtration and used to rinse the reactor. The filtrate was concentrated to a volume of approximately 0.45 L to form a clear solution. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
48% | With caesium carbonate;tris-(dibenzylideneacetone)dipalladium(0); 2,2'-bis-(diphenylphosphino)-1,1'-binaphthyl; In toluene; at 85℃; for 24h; | l-(4-{4-r3-d-Difluoromethyl-lH-benzoimidazol-2-yl)-phenvn- piperazine- 1 -carbonyl } - 1 ,4] diazepan- 1 -vQ-ethanone Method J - Step c- 2-(3-Bromo-phenyl)-l-difluoromethyl-lH- benzoimidazole (0.10 g, 0.31 mmol), cesium carbonate (0,14 g, 0.43 mmol), rac-2,2' bis(diphenylphosphino)-l,l'-binaphtyl (BINAP) (0.007 g, 0.01 mmol) and tris- (dibenzilideneacetone)-dipalladium(O) (0.004 g) were placed into a 7 mL sealed vial and purged by repeated nitrogen/vacuum cycles for ten minutes. Dry toluene (0.6 mL) and N-acetylhomopiperazine (0.05 mL, 0.37 mmol) were added and reaction mixture was heated at 85C for 24 hours with stirring.Reaction was cooled to room temperature and filtered through SCX cartridge (2 g), (eluent: DCM/methanol 1 : 1). The organic layer was concentrated under reduced pressure and purified by preparative HPLC to afford 58 mg of the title compound (48%).1H-NMR (400 MHz, CD3OD): delta 1.95-2.08 (5H, m), 3.48-3.55 (2H, m), 3.65-3.77 (4H, m), 3.80-3.84 (2H, m), 6.93-6.95 (IH, m), 7.04-7.11 (2H, m), <n="45"/>7.41-7.67 (4H, m), 7.73-7.82 (2H, m). m/z 385 (M+H)+; retention time= 3.30. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
First Approach; A solution of 5-[4-(Tetrahydro-pyran-2-yloxy)-phenyl]-2H-pyrazol-3-ylamine (700 mg, 2.70 mmol) and diisopropylethylamine (697.8 mg, 5.40 mmol) in dry DMA (15 mL) was cooled to -10 C. (ice/water bath) under N2; a solution of 5-bromovaleryl chloride (538.5 mg, 2.70 mmol) in dry DMA (5 mL) was added over 30 min. After 10 min at -10 C., completion of the reaction as monitored by LC-MS was generally observed. Acetylhomopiperazine (959.7 mg, 6.75 mmol) and NaI (404.6 mg, 2.70 mmol) were then added and the reaction heated at 40 C. overnight. The reaction was checked by HPLC-MS and 5-(4-Acetyl-[1,4]diazepan-1-yl)-pentanoic acid {5-[4-(tetrahydro-pyran-2-yloxy)-phenyl]-2H-pyrazol-3-yl}-amide was the main product, with 15% of 5-chloro-pentanoic acid {5-[4-(tetrahydro-pyran-2-yloxy)-phenyl]-2H-pyrazol-3-yl}-amide present as impurity. The solvent was evaporated and the product was purified by preparative HPLC. The title compound 5-(4-acetyl-[1,4]diazepan-1-yl)-pentanoic acid {5-[4-(tetrahydro-pyran-2-yloxy)-phenyl]-2H-pyrazol-3-yl}-amide was obtained contaminated with 10% of an unknown impurity (370 mg). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
19% | Second ApproachA solution of 5-[4-(tetrahydro-pyran-2-yloxy)-phenyl]-2H-pyrazol-3-ylamine (1000 mg, 3.86 mmol) and diisopropylethylamine (997 mg, 7.71 mmol) in dry DMA (20 mL) was cooled to -10 C. (ice/water bath) under N2; a solution of 5-bromovaleryl chloride (769 mg, 3.86 mmol) in dry DMA (5 mL) was added over 30 min. After 10 min at -10 C., completion of the reaction as monitored by LC-MS was generally observed. Acetylhomopiperazine (1371 mg, 9.64 mmol) and NaI (578 mg, 3.86 mmol) were then added and the reaction heated at 40 C. overnight. The reaction was checked by HPLC-MS and 5-(4-acetyl-[1,4]diazepan-1-yl)-pentanoic acid {5-[4-(tetrahydro-pyran-2-yloxy)-phenyl]-2H-pyrazol-3-yl}-amide was the main product, with 15% of 5-chloro-pentanoic acid {5-[4-(tetrahydro-pyran-2-yloxy)-phenyl]-2H-pyrazol-3-yl}-amide present as impurity. The solvent was evaporated and the reaction mixture treated with hot water. 5-chloro-pentanoic acid {5-[4-(tetrahydro-pyran-2-yloxy)-phenyl]-2H-pyrazol-3-yl}-amide precipitated as a white solid and was filtered off. The water phase was treated with saturated NaHCO3 (10 mL) and the 5-(4-acetyl-[1,4]diazepan-1-yl)-pentanoic acid {5-[4-(tetrahydro-pyran-2-yloxy)-phenyl]-2H-pyrazol-3-yl}-amide obtained in the first approach was combined to this solution. The water phase was extracted with DCM and the product precipitated as a sticky white solid at the interphase. The product was recovered, treated with 2 N HCl and purified by preparative HPLC and converted to the HCl salt with HCl in Et2O.(531 mg, combined yield: 19%).C21H29N5O3 Mass (calculated) [399]; (found) [M+H+]=400.LC Rt=double peaks 0.35 min, 1.12 min, 99% (10 min method)1H-NMR (DMSO-d6): 1.52-1.60 (2H, m); 1.63-1.72 (2H, m); 2.00 (3H, s); 2.02-2.11 (1H, m); 2.15-2.25 (1H, m), 2.28-2.38 (2H, m), 2.88-3.00 (1H, m), 3.02-3.12 (2H, m), 3.12-3.20 (1H, m), 3.30-3.60 (4H, m), 3.75-3.85 (1H, m), 3.95-4.05 (1H, m), 6.68 (1H, s), 6.79 (2H, d, J=8.7 Hz), 7.49 (2H, d, J=8.7 Hz), 10.44 (1H, s). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
46% | With sodium iodide; In ISOPROPYLAMIDE; at 60℃; for 18h;Product distribution / selectivity; | To 750 mg (1.96 mmol) of 5-bromo-pentanoic acid [5-(4-methoxy- phenyl)-2H-pyrazol-3-yl]-amide in 7 mL of DMA, 7V-acetyl-diazepine (278 mg, 1.96 mmol) and NaI (240 mg, 1.96 mmol) were added and the reaction heated at 60 0C for 18 hours. Upon complete conversion (as monitored by LC-MS) the mixture was diluted with 20 mL of DCM and washed with water. The organic phase was concentrated under reduced pressure to afford a residue which was purified with a SiO2 column ( 10 g) eluting with a gradient from DCM to MeOH 90: 10. The title compound (380 mg) was recovered pure (yield 46%).C22H3IN5O3 Mass (calculated) [413]; (found) [M+H+]=414 LC Rt = 1.91, 100% (10 min method)1H-NMR (400 MHz, DMSO-d6): delta 1.53-1.75 (4H, m), 1.90-2.15 (5H, m), 2.28-2.42 (2H, m), 2.90-3.26 (3H, m), 3.34-3.58 (3H, m), 3.71-3.88 (7H, m) |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
70% | In 1,4-dioxane; at 85℃; | A solution of N-(7-chloropyrazolo[ 1 ,5-a]pyrimidin-5-yl)-4-(2-hydroxypropan-2- yl)benzamide (2D, 200 mg,0.604 mmol) and l-(l,4-diazepan-l-yl)ethanone (130 mg,0.906 mmol) in Dioxane (6 mL) was stirred at 85 0C overnight. After cooling to room temperature, the mixture was diluted with a few drops of DMSO and methanol, and was then purified by preparatory HPLC, 5-95% (MeCN/H2O gradient + 0.01 % TFA). Lyophilization of the combined fractions gave the titled compound as a white solid (182.5 mg, 70%). 1H NMR (METHANOL-d4) delta: 7.89 - 7.99 (m, 6H), 7.62 - 7.68 (m, 4H), 7.34 (d, J = 8.6 Hz, 2H), 6.26 (t, J = 2.3 Hz, 2H), 4.47 (t, J = 5.7 Hz, 2H), 4.18 - 4.30 (m, 2H), 4.05 (dt, J = 16.2, 6.0 Hz, 4H), 3.82 (dt, J = 11.6, 5.8 Hz, 4H), 3.67 (dt, J = 8.7, 6.0 Hz, 4H), 2.19 (t, J = 5.9 Hz, 2H), 2.13 (s, 3H),2.03 - 2.11 (m, 2H), 1.90 (s, 3H), 1.56 (s, 12H). ESI-MS: m/z 437.1 (M+H)+. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
78% | In N,N-dimethyl-formamide; at 100℃; for 2h; | A solution of lambda/-(7-chloro-2-methylpyrazolo[l,5-alpha]pyrimidin-5-yl)-4-(2- hydroxypropan-2-yl)benzamide (2F, 86 mg, 0.25 mmol) and l-(l,4-diazepan-l-yl)ethanone (101 mg, 0.75 mmol) in DMF (1.0 mL) was stirred at 100 0C for 2h. After cooling to room temperature, the mixture was diluted with a few drops of DMSO and methanol, and was then purified by preparatory HPLC (25-40% MeCN/H2O gradient + 0.01% TFA). Lyophilization of the combined fractions gave the titled compound as a white solid (87.7 mg, 78%). 1H NMR (DMSO-de) [1 :1 ratio of rotamers: delta: 10.93 (s, IH); 10.91 (s, IH)], 7.99 (d, J = 8.3 Hz, 2H), 7.62 (dd, 2H), [1 :1 ratio of rotamers: 7.13 (s, IH); 7.07 (s, IH)], [1 :1 ratio of rotamers: 6.19 (s, IH); 6.18 (s, IH)], [1 :1 ratio of rotamers: 4.37 (t, J = 5.6 Hz, 2H); 4.20 (t, J = 5.4 Hz, 2H)], [1 :1 ratio of rotamers: 4.03 (t, J = 5.6 Hz, 2H); 3.97 (t, J = 5.9 Hz, 2H)], 3.63 - 3.78 (m, 2H), [1 :1 ratio of rotamers: 3.58 (t, J = 5.9 Hz, 2H); 3.52 (t, J = 5.8 Hz, 2H)], 2.37 (s, 3H), [1 :1 ratio of rotamers: 2.03 - 2.11 (m, 2H); 1.94 (quin, J = 5.9 Hz, 2H)], [1 :1 ratio of rotamers: 2.02 (s, 3H); 1.89 (s, 3H)], 1.46 (s, 6H); ESI-MS: m/z 451.3 (M+H)+. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
51% | In 1-methyl-pyrrolidin-2-one; at 120℃; for 0.5h;Microwave irradiation; | In a 2 mL microwave vial was placed lambda/-(7-chloro-2-cyclopropylpyrazolo[ 1 ,5- alpha]pyrimidin-5-yl)-4-(2-hydroxypropan-2-yl)benzamide (2H, 75 mg, 0.21 mmol) and N- <n="304"/>PATENT ASKl -5001 -WO acetylhomopiperazine (59 mg, 0.42 mmol). To the sealed vial was then added NMP (2 ml) and the mixture was then heated in the microwave at 120 0C for 30 minutes. After cooling to room temperature, the reaction mixture was partitioned between brine and EtOAc. The aqueous layer was extracted once more with EtOAc, and the combined organic layers were dried over MgSO4, filtered and concentrated in vacuo. The crude product was purified by recrystallization from ether and EtOAc to give the titled compound (50 mg, 51 % yield) as an off-white solid. ESI-MS: m/z 465 (M+H)+. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With N-ethyl-N,N-diisopropylamine; HATU; In N,N-dimethyl-formamide; for 0.5h; | Synthesis 12; 1 -[4-(5-Phenyl-thiophene-3-carbonyl)-[1 ,4]diazepan-1 -yl]-ethanone (AA-27); delta-Phenyl-thiophene-S-carboxylic acid (0.1 g, 0.5 mmol) was dissolved in DMF (3 mL). 1-[1 ,4]Diazepan-1-yl-ethanone (0.5 mmol), DIPEA (1.5 mmol) and HATU (0.5 mmol) were added and the reaction mixture stirred for 0.5 hours. Ethyl acetate (20 mL) was added and the organic solution was washed with 1 N hydrochloric acid, dried with magnesium sulfate, filtered and the solvent removed by evaporation. The residue was purified by HPLC, eluting with 70%-90% acetonitrile in water (0.1 % formic acid) over 30 minutes. The fractions containing the desired product were concentrated under vacuum and freeze-dried to give the title compound (28 mg). LCMS m/z 329.20 [M+H]+ RX= 8.20 min (Analytical Method 1). 1H NMR (400 MHz, CHCI3-d): delta 7.6 (m, 2H), 7.55-7.3 (m, 5H), 3.9-3.5 (m, 8H), 2.1 (s, 3H), 2.0-1.3.2 (m, 2H). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With N-ethyl-N,N-diisopropylamine; HATU; In dichloromethane; at 40℃; for 1h; | A mixture of the product of example Ii (160 mg), JV-acetylhomopiperazine (89 mg), DIPEA (370 muL) and HATU (192 mg) in dichloromethane (5 ml) was stirred at 400C for 1 h. The reaction mixture was diluted with ethyl acetate and washed with an aqueous HCl solution (0.2 M), water and brine. The organic layer was dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by chromatography on silica gel in heptane/ethyl acetate [10/0 ? 8/2 (v/v)] as eluent.Yield: 230 mg; hFSHRago (CHO luc) EC50 = 5.2 nM |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
Example 35-(4-Acetyl-[ 1,4] diazepam- l-yl)-pentanoic acid (5-thiophen-2-yl-lH-pyrazol-S-yl)-amide; [0295] Bromovaleryl chloride (1.62 mL, 12.12 mmol) was dissolved in DMA (50 mL).To this, a solution of 5-thiophen-2-yl-2H-pyrazol-3-ylamine (2 g, 12.12 mmol) and DIEA (2.1 mL, 12.12 mmol) was added portionwise at 0 C. The reaction mixture was left stirring 1 hour at 0C and then for 2 hours at room temperature. After a total of 3 hours, PS-Trisamine (1 g, ~4mmol/g) was added to the mixture and left stirring for 2 hours. Then, N-acetylhomopiperazine (4.3 g, 30.3 mmol) was added and the mixture was left stirring at room temperature for a further 60 hours. After DMA evaporation under reduced pressure, water was added (50 mL) and this was extracted with ethyl acetate (3 x 30 mL). The aqueous layer was basified with solid NaOH and extracted with ethyl acetate at pH=10 and then again at pH=l 1. All the organic phases were reunited, dried and evaporated. The residue was purified by silica chromatography eluting with a gradient of ethyl acetate/methanol 9:1 up to ethyl acetate/methanol 8:2, to give the title compound as yellowish oil (800 mg, 17%).C19H27N5O2S Mass (calculated) [389.52]; (found) [M+H+]=390.11NMR (400 MHz, CDCl3): 1.52 (2H, m); 1.77 (2H, m); 1.82 (2H, m); 2.13+2.09 (3H, s); 2.44 (2H, m);2.56 (2H, m); 2.62 (1H, m); 2.76-2.70 (3H, m); 3.51 (2H, m); 3.61 (1H, m); 3.64 (1H, m); 6.48 (1H, s); 6.56 (1H, s); 7.05-7.02 (2H, m); 6.9-7.26 (2H, m); 8.94 (1H, s); 9.53 (1H, s).[0296] The title compound was converted in its hydrochloride salt by adding a solution of HCl (1.05 mL, 2 N) in diethyl ether to (5-(4-Acetyl-[1,4]diazepan-1-yl)-pentanoic acid (5- thiophen-2-yl-2H-pyrazol-3-yl)-amide (80 Omg, 2.05 mmol) suspended in MeOH (10 mL). The solution was left stirring at room temperature for 1 hour, then evaporated to dryness to yield the title compound as a yellowish powder (750 mg, 86%) |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
54% | In 1-methyl-pyrrolidin-2-one; at 190℃; for 2h;Microwave irradiation; | Step 4 : l-(4-(5-amino-6-(6-methyl-lH-benzo[d]imidazol-2-yl)pyrazin-2-yl)-l,4-diazepan-l- yl)ethanone (Compound 1-1)[00213] A mixture of 5-bromo-3-(6-methyl-lH-benzimidazol-2-yl)pyrazin-2-amine (100 mg,0.3288 mmol) and l-(l,4-diazepan-l-yl)ethanone (701 mg, 4.932 mmol) in NMP (200.0 muL) was heated at 19O0C in the microwave for 2 hours. The reaction mixture was partitioned betweenDCM and water and the organics separated and concentrated to dryness. The resultant residue was purified by reverse phase preparative HPLC [Waters Sunfre C 18, lOuM, IOOA column, gradient 10% - 95%B (solvent A: 0.05% TFA in water, solvent B: CH3CN) over 16 minutes at25mL/min]. The fractions were collected, passed through a sodium bicarbonate cartridge and freeze-dried to give the title compound (67.7mg, 54% Yield). IH NMR (400.0 MHz, DMSO) d1.80 -1.94 (2H, m), 1.78 (3H, s), 2.43-2.46 (3H, s), 3.40 (2H, m), 3.63-3.83 (5H, m), 3.92 (IH, m), 7.04-7.11 (3H, m), 7.38-7.59 (2H, m), 7.90 (IH, m), 12.37 (IH, m) ppm; MS (ES+) 366 |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
A solution of the product of 5Od (60 mg) in dioxane (1 ml) was treated with a solution of LiOH (20 mg) in water (0.3 ml). The mixture was stirred for 45 min and neutralized by addition of an aqueous HCl solution (0.5 N). The aqueous material was freeze-dried and diluted with DMF (1 ml). N-acetylhomopiperidine (30 mg), N-ethylmorpholine (30 ml) and TBTU (60 mg) were added. The reaction mixture was stirred for 4 h, poured in water and extracted with ethyl acetate. The organic layer was dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by chromatography on silica gel (dichloromethane/acetone as eluent) . The product was dissolved in a mixture of acetone/ ether (v:v ,1 :1) and treated with one equivalent of a 0.4N HCl solution in ether. Yield: 10 mg. MS-ESI: [M+H]+ = 493.4; TLC Rf = 0.50 (dichloromethane/acetone 1 :1); NMR (DMSO-de) delta 2.00 (m, 3, acetyl(rotamers)), 3.47 and 3.80 (2x s, 6, OCH3), 6.95 and 7.02 (2xs, 2, H7 and HlO), 7.30 and 7.69 (2x m, F-Ar-H); 119Ttau -NMR (DMSO-d6) - 114.9; hFSHRago (CHO luc) EC50 = 315 nM. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With N-ethylmorpholine;; O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate; In N,N-dimethyl-formamide; for 4h; | (e). 1-{4-[1-(4-Fluoro-phenyl)-8,9-dimethoxy-5,6-dihydro-imidazo[5,1-a]isoquinoline-3-carbonyl]-[1,41]diazepan-1-yl}-ethanone; hydrochloride salt A solution of the product of 50d (60 mg) in dioxane (1 ml) was treated with a solution of LiOH (20 mg) in water (0.3 ml). The mixture was stirred for 45 min and neutralized by addition of an aqueous HCl solution (0.5 N). The aqueous material was freeze-dried and diluted with DMF (1 ml). N-acetylhomopiperidine (30 mg), N-ethylmorpholine (30 ml) and TBTU (60 mg) were added. The reaction mixture was stirred for 4 h, poured in water and extracted with ethyl acetate. The organic layer was dried (MgSO4), filtered and concentrated in vacuo. The residue was purified by chromatography on silica gel (dichloromethane/acetone as eluent). The product was dissolved in a mixture of acetone/ether (v:v, 1:1) and treated with one equivalent of a 0.4N HCl solution in ether. Yield: 10 mg. MS-ESI: [M+H]+=493.4; TLC Rf=0.50 (dichloromethane/acetone 1:1); NMR (DMSO-d6) delta 2.00 (m, 3, acetyl(rotamers)), 3.47 and 3.80 (2*s, 6, OCH3), 6.95 and 7.02 (2*s, 2, H7 and H10), 7.30 and 7.69 (2*m, F-Ar-H); 19F-NMR (DMSO-d6)-114.9; hFSHRago (CHO luc) EC50=315 nM. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With N-ethyl-N,N-diisopropylamine; HATU; In dichloromethane; at 20℃; for 16h; | A mixture of 37 mg of 3b, 47 mg of HATU, 60 mul of DiPEA and 20 mg of <strong>[61903-11-5]1-(1,4-diazepan-1-yl)ethanone</strong> in 0.5 ml of dichloromethane was stirred at RT for 16 hr. The reaction was diluted with 3 ml of 0.5N HCl and extracted with dichloromethane. The organic extract was washed once with 5% aq. NaHCO3, dried and concentrated. The crude material was purified by chromatography over reversed-phase silica gel, using a gradient of acetonitrile/water, to give 23 mg of 3c; MS-ESI: [M+H]+ 521.5. NMR (CDCl3) delta 7.48 (m, 2, Ar(F)H), 7.19 (m, 2, Ar(F)H), 6.81 (2×s, 1, ArH-rotamers, 6.30 (2×s, 1, ArH rotamers), 3.97 (m, 1, CH isoC3H7), 3.86 (s, 3, OCH3), 3.52-4.04 (m, 8, CH2 azepine) 2.90-2.98 (m, 4, CH2CH2), 2.14 (2×s, 3, CH3 rotamers) 1.87 and 2.03 (2×m, 2, CH2 azepine), 1.16 (d, 6, isoC3H7). | |
With N-ethyl-N,N-diisopropylamine; HATU; In dichloromethane; at 20℃; for 16h; | A mixture of 37 mg of 3b, 47 mg of HATU, 60 mul of DiPEA and 20 mg of 1-(1,4- diazepan-l-yl)ethanone in 0.5 ml of dichloro methane was stirred at RT for 16 hr. The reaction was diluted with 3 ml of 0.5N HCl and extracted with dichloromethane. The organic extract was washed once with 5% aq. NaHCO3, dried and concentrated. The crude material was purified by chromatography over reversed-phase silica gel, using a gradient of acetonitrile/water, to give 23 mg of 3c ; MS-ESI: [M+H]+ 521,5. NMR (CDCl3) delta 7.48 (m, 2, Ar(F)H), 7,19 (m, 2, Ar(F)H), 6.81(2xs, 1, ArH-rotamers, 6.30 (2xs, 1, ArH rotamers), 3.97 (m, 1, CH oC3H7), 3.86 (s, 3, OCH3),3.52-4.04 (m, 8, CH2 azepine) 2.90-2.98 (m, 4, CH2CH2),2.14 (2x s, 3, CH3 rotamers)1.87 and 2.03 (2xm, 2, CH2 azepine), 1.16 (d, 6, oC3H7) . |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With sodium carbonate; In ethanol; for 2h;Reflux; | Example A.3,2; 2-(4-Acetvl-lf4-diaze&an-l-yl)-Lambda/-cyciohexylaeetanr>tde (002NK24) l-(l,4-Diazepan-l-yl)ethanone (1 mmol, 127 mg) in ethanol (0.5 mL) was added to 2- chloro-/V-cyclohexylacetamide (1.1 mmol, 193 mg) and sodium carbonate (1.1 mmol, 117 mg) in ethanol (2 mL) and the reaction was heated to reflux for 75 minutes. Sodium carbonate (1.9 mmol, 205 mg) was added and the reaction was heated to reflux for an additional 45 minutes. Dowex 50WX2 hydrogen form 100-200 mesh (4g) was washed with methanol (40 mL). The reaction mixture was filtered then loaded onto the ion exchange resin using gravity filtration. The reaction flask was washed with methanol (2 mL) and this was filtered and loaded onto the resin and the resin was washed with methanol (40 mL). The product was eluted off the resin with ca. IM NH3 in methanol (20 mL) and the solution was concentrate to give 2-(4-acetyl-l,4-diazepan-l-yl)-/V- cyclohexylacetamide (247 mg, 88%) as pale yellow oil.1H NMR (CD3OD, mixture of 2 rotamers in ca. 1 : 1 ratio) delta 3.60 (IH, m, CO-NH-CH), 3.61 (4H, m, diazepane), 3.16 (IH, s, CO-CH2-N), 3.14 (IH, s, CO-CH2-N), 2.83 (IH, m, diazepane), 2.73 (3H, m, diazepane), 2.13 (3/2H, s, CH3-CO), 2.11 (3/2H, s, CH3-CO), 1.95-1.7 (2H, m, diazepane), 1.95-1.7 (4H, m, cyclohexyl), 1.64 (IH, m, cyclohexyl), 1.5-1.2 (5H, m, cyclohexyl).HPLC phosphate buffer: Rt 6.19 mins (94.5% pure). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
51% | In methanol; at 20℃; for 24h; | General procedure: A solution of 5-bromo-5-(4-phenoxyphenyl)pyrimidine-2,4,6(1H,3H,5H)-trione (1.0 mmol) in methanol (5 ml) was treated with the substituted piperazines or homopiperazines (2 mmol) and stirred for 24 h at ambient temperature. Compounds 8a, 8b, 8c, 8f, and 8g precipitated. The precipitates were collected by filtration and dried in vacuo to afford the solids. In the case of compounds 8d, 8e, 8h, 8i and 9a-d, the solvents of reactions were removed and the residues purified by flash column chromatography and dried to yield the pure solids. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
12.2% | With sodium tris(acetoxy)borohydride; dimethyl sulfoxide; zinc(II) chloride;Inert atmosphere; | A mixture of 2- { [2-( { [ 1 ,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)- 1 H-pyrazolo [3,4- b]pyridin-5-yl]methyl}amino)-2-oxoethyl]oxy}-N-[(6-fluoro-3'-formyl-3- biphenylyl)methyl]acetamide (35 mg, 0.055 mmol), l-acetylhexahydro-lH-l,4-diazepine (55.5 mg, 0.55 mmol), ZnCl2 (5 mg, 0.036 mmol) and NaBH(OAc)3 (117 mg, 0.55 mmol) in DMSO (1 mL) was stirred under argon. The crude product was purified to give 2-({2-[({3'-[(4- acetylhexahydro- IH- 1 ,4-diazepin- 1 -yl)methyl]-6-fluoro-3-biphenylyl}methyl)amino]-2- oxoethyl}oxy)-N- [l,6-diethyl-4-(tetrahydro-2H-pyran-4-ylamino)-lH-pyrazolo[3,4-Z7]pyridin-5- yl]methyl}acetamide (5.02 mg, 12.2 %). m.p. 108-111 0C. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
93.0% | With triethylamine; In ethanol; at 20℃; for 1h;Inert atmosphere; | A mixture, at ambient temperature and in a nitrogen atmosphere, of 4-ethoxy-3-(1-methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)benzene-1-sulfonyl chloride (1.0 g, 2.4 mmol) in ethanol (10 mL)is slowly added to a mixture of 1,4-diazepane (0.25 g, 2.4 mmol) and triethylamine (0.37 g, 3.64 mmol) in ethanol (10 mL). After one hour, eliminate the solvent, dissolve the product in dichloromethane and wash with brine. Dry the organic phase and eliminate the solvent to obtain compound 1 with a 36.25% yield.; The product was analyzed giving the following results: white solid; m.p. 156-159C. IR numax (cm-1): 3299, 2932, 1698, 1601, 1534, 1487, 1467, 1330, 1246, 1155, 1027, 813, 759 ( Figure 1 ). RMN 1H (200 MHz, CDCl3) delta (ppm): 1.02 (t, 3H, J= 7.0 Hz); 1.65 (t, 3H, J= 7.0 Hz); 1.86 (m, 4H); 2.93 (m, 6H); 3.45 (m, 4H); 4.25 (s, 3H); 4.35 (c, 2H, J= 7.0 Hz); 7.14 (d, 1H, Jo = 8.8 Hz); 7.88 (dd, 1H, Jm = 2.6 Hz, Jo = 8.8 Hz); 8.85 (d, 1H, Jm = 2.6 Hz); 10.91 (a, 1H), ( Figure 2 ). ESI/EM: [M+1]+ 475 m/z ( Figure 3 ).; Examples 8 to 11 were performed under the experimental conditions described in example 1, changing only the stoichiometric ratio to 1:1.1 for the chlorosulfonyl derivate and the suitable derivates of 1,4-diazepane, respectively (Table 3). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
71% | With sodium carbonate; potassium iodide; In ethanol; for 18h;Reflux; | General procedure: 5.1.4. Example A.6.1: general procedure 3 (GP3). The amine (1.0equiv) in ethanol (1mL per mmol amine) was added to the alkyl halide (1.1equiv) and sodium carbonate (3equiv) in ethanol (2mL per mmol amine). The reaction was heated to reflux then water (5mL per mmol amine) and aqueous sodium carbonate (1M, 5mL per mmol amine) were added. The product was extracted with ethyl acetate (3 times, 10mL per mmol amine) and the combined organic layers were dried over MgSO4, filtered and concentrated. The crude material was purified using the Combiflash (A buffer Et2O, B buffer 0.1M NH3 in 1:1 MeOH/Et2O) and the relevant fractions combined and concentrated to give the product. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
70% | With potassium carbonate; In N,N-dimethyl-formamide; at 120℃; for 20h; | A mixture of 4-fluorobenzaldehyde (1.56 g, 12.6 mmol), <strong>[61903-11-5]1-(1,4-diazepan-1-yl)ethanone</strong> (1.5 g, 10.5 mmol), and K2CO3 (1.74 g, 12.6 mmol) in DMF (10 mL) were heated at 120 C. for 20 hours. The mixture was cooled to room temperature and diluted with water. The mixture was extracted with ethyl acetate and the organic phase washed with brine, dried over anhydrous MgSO4, filtered, and concentrated. The residue was purified by flash chromatography on silica gel, eluting with 50% ethyl acetate/hexanes to 100% ethyl acetate to 10% methanol/ethyl acetate, to afford 4-(4-acetyl-1,4-diazepan-1-yl)benzaldehyde (1.8 g, 70%) |
70% | With potassium carbonate; In N,N-dimethyl-formamide; at 120℃; for 20h; | Example 32 Preparation of 2-(4-(4-Acetyl-1,4-diazepan-1-yl)phenyl)-5,7-dimethoxyquinazolin-4(3H)-one A mixture of 4-fluorobenzaldehyde (1.56 g, 12.6 mmol), <strong>[61903-11-5]1-(1,4-diazepan-1-yl)ethanone</strong> (1.5 g, 10.5 mmol), and K2CO3 (1.74 g, 12.6 mmol) in DMF (10 mL) were heated at 120 C. for 20 hours. The mixture was cooled to room temperature and diluted with water. The mixture was extracted with ethyl acetate and the organic phase washed with brine, dried over anhydrous MgSO4, filtered, and concentrated. The residue was purified by flash chromatography on silica gel, eluting with 50% ethyl acetate/hexanes to 100% ethyl acetate to 10% methanol/ethyl acetate, to afford 4-(4-acetyl-1,4-diazepan-1-yl)benzaldehyde (1.8 g, 70%). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
94% | In N,N-dimethyl-formamide; at 60℃; for 48h; | (Formula 7-6: methyl 4-((4-acetyl-N-(pyridin-2-yl)-1,4-diazepane-1-carboxamido)methyl)benzoate)[1003][1004]Compound ofFormula 7-5(methyl 4-((((4-nitrophenoxy)carbonyl)(pyridin-2-yl)amino)methyl)benzoate; 0.40 g, 0.74 mmol) was dissolved in dimethylformamide (10 mL), and then <strong>[61903-11-5]1-(1,4-diazepane-1-yl)ethanone</strong> (0.102 mL, 1.08 mmol) was added, and the mixture was heated and stirred at 60 for 2 days. Then, the dimethylformamide was removed under reduced pressure, water was poured into the reaction mixture, and the organic layer was extracted with ethyl acetate. The organic layer was washed with saturated sodium chloride aqueous solution, dehydrated with anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified and concentrated by column chromatography (silica; methanol/dichloromethane=5%) to give the desired compound ofFormula 7-6(0.378 g, 94%) in the form of a white oil. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With sodium tris(acetoxy)borohydride; acetic acid; zinc(II) chloride; In diethyl ether; dichloromethane; N,N-dimethyl-formamide; at 25℃; for 19h;Inert atmosphere; | Example 97: Preparation of l-(4-{6-[5-(2H-Pyrazol-3-yl)-pyridin-2-yloxy]- benzofuran-3-ylmethyl}-[l,4]diazepan-l-yl)-ethanone (97) To a solution of 97-1 (46 mg, 0.32 mmol) in a mixture of DCM (3 mL) and DMF (2 mL) is added glacial AcOH (12 mu, 0.21 mmol) and ZnCl2 (1.0 M in Et20, 0.27 mL). Next, G (60 mg, 0.13 mmol) and sodium triacetoxyborohydride (250 mg, 1.16 mmol) are added sequentially, and the resultant reaction is stirred at ambient temperature. After 1 h, additional amount of 97-1 (64 mg, 0.45 mmol) and sodium triacetoxyborohydride (75 mg, 0.35 mmol) are added. After 18 h, the reaction is diluted with EtOAc (50 mL), and washed with saturated aqueous NaHCC>3 (50 mL) and brine (20 mL). The aqueous layer is extracted with EtOAc (50 mL). The combined organic layers are dried over Na2S04, filtered and concentrated to give 97-2. To a solution of 97-2 (130 mg, 0.231 mmol) in DCM (5 mL) is added TFA (5 mL), and the reaction is stirred at ambient temperature for 2 h. The mixture is concentrated; the residue is dissolved in DCM (20 mL), and treated with a solution of 2M NH3 in MeOH (10 mL). The mixture is concentrated and the residue is purified by silica gel chromatography (0- 10% MeOH in DCM) to give the title product (97). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
23.5% | With N-ethyl-N,N-diisopropylamine; In dichloromethane; at 20℃; for 18h; | A solution of N-(4-(5-(difluoromethyl)- 1,3 ,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), N-acetylhomopiperazine (0.073 g, 0.511 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichioromethane (5 mL) was stilTed at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (Si02, 12 g cartridge; methanol / dichloromethane = 3 % to 5 %) to give2-(4-acetyl- 1 ,4-diazepan- 1 -yl)-N-(4-(5-(difluoromethyl)- 1,3 ,4-oxadiazol-2-yl)benzyl)- N-phenylethane-1-sulfonamide as white solid (0.032 g, 23.5 %).?H NMR (700 MHz, CDC13) oe 8.04 - 8.00 (m, 2 H), 7.45 (d, 2 H, J = 8.3 Hz), 7.36 -7.27 (m, 5 H), 6.91 (t, 1 H, J= 51.7 Hz), 4.96 (s, 2 H), 3.68 - 3.66 (m, 1 H), 3.64- 3.59(m, 1 H), 3.56 - 3.51 (m, 2 H), 3.36 - 3.33 (m, 1 H), 3.32 - 3.27 (m, 1 H), 3.13 - 3.07(m, 2 H), 2.79-2.66 (m, 4 H), 2.11 -2.09 (m, 3 H), 1.97 (m, 1 H), 1.88 - 1.87 (m, 1H);LRMS (ES) mlz 534.3 (M+1). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
99.5% | [ 1395] To a stirred solution of methyl 4-((phenylamino)methyl)benzoate (0.500 g, 2.072 mmol) in dichloromethane (20 mL) were added at 0 C triphosgene (0.492 g, 1.658 mmol) and N.N-diisopropylethylamine ( 1.810 mL, 10.361 mmol). The reaction mixture was stirred at the same temperature for 1 hr, treated at the room temperature with l-( l ,4-diazepan-l-yl)ethan-l -one (0.354 g, 2.487 mmol), and stirred for additional 2 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture w-as passed through a plastic frit to remove solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo. The concentrate was purified and concentrated by column chromatography (Si02, 12 g cartridge; methanol / dichloromethane = 0 % to 5 %) to give the title compound methyl 4-((4-acetyl-N-phenyl- l ,4-diazepane- l -carboxamido)methyl)benzoate as pale yellow oil (0.844 g, 99.5 %). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
38.9% | In acetonitrile; at 100℃; for 18h; | [5673] 3-(2-bromoethy 1)- 1 -(4-(5-(difluoromethyl)- 1 ,3,4-oxadiazol-2-yl)-2-fluorobenzyl)- 1 -p henylurea (0.050 g, 0. 107 mmol) and l-( l ,4-diazepan- l-yl)ethan- l-one (0.017 g, 0.1 17 mmol) were mixed at the room temperature in acetonitrile ( 1 mL) and then stirred at 100 C for 18 hr and cooled down to the room temperature to terminate the reaction. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The bi-phasic mixture was passed through a plastic frit to remove the solid residues and aqueous layer, and the organic layer collected was concentrated in vacuo. The concentrate was purified and concentrated by column chromatography (Si02 plate, 20x20x 1 mm; methanol / dichloromethane = 10 %) to give 3-(2-(4-acetyl- 1 ,4-diazepan- 1 -yl)ethyl)- 1 -(4-(5-(difluoromethyl)- 1 ,3,4-oxadiazol-2-yl)- 2- fluorobenzyl)- l -phenylurea as yellow oil (0.022 g, 38.9 %). [5674] NMR (700 MHz, CDC1,) delta 7.89 (dt, 1 H, J = 7.9, 1.2 Hz), 7.75 - 7.67 (m, 2H), 7.43 - 7.37 (m, 2H), 7.37 - 7.30 (m, 1 H), 7.21 - 7.16 (m, 2H), 7.04 - 6.82 (m, 1 H). 5.10 - 5.02 (m, 1 H), 5.05 (s, 2H), 3.43 (t, 1 H, J = 6.3 Hz), 3.41 (t, 1H, J = 5.0 Hz), 3.33 (t, 1H, J = 6.3 Hz), 3.32 - 3.26 (m, 3H), 2.61 - 2.57 (m, 1 H), 2.57 - 2.4.7 (m, 5H), 2.08 - 2.04 (m, 3H), 1.71 (s, 1 H), 1.62 (dt, 2H, / = 12.0, 6.0 Hz); LRMS (ES) m/z 531.0 (M+ + 1 ). |
Tags: 61903-11-5 synthesis path| 61903-11-5 SDS| 61903-11-5 COA| 61903-11-5 purity| 61903-11-5 application| 61903-11-5 NMR| 61903-11-5 COA| 61903-11-5 structure
[ 344779-07-3 ]
4-(2-(Dimethylamino)ethyl)-1,4-diazepan-5-one
Similarity: 0.89
[ 329794-41-4 ]
4-Methyl-1,4-diazepan-5-one hydrochloride
Similarity: 0.86
[ 344779-07-3 ]
4-(2-(Dimethylamino)ethyl)-1,4-diazepan-5-one
Similarity: 0.89
[ 329794-41-4 ]
4-Methyl-1,4-diazepan-5-one hydrochloride
Similarity: 0.86
[ 344779-07-3 ]
4-(2-(Dimethylamino)ethyl)-1,4-diazepan-5-one
Similarity: 0.89
[ 329794-41-4 ]
4-Methyl-1,4-diazepan-5-one hydrochloride
Similarity: 0.86
Precautionary Statements-General | |
Code | Phrase |
P101 | If medical advice is needed,have product container or label at hand. |
P102 | Keep out of reach of children. |
P103 | Read label before use |
Prevention | |
Code | Phrase |
P201 | Obtain special instructions before use. |
P202 | Do not handle until all safety precautions have been read and understood. |
P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
P211 | Do not spray on an open flame or other ignition source. |
P220 | Keep/Store away from clothing/combustible materials. |
P221 | Take any precaution to avoid mixing with combustibles |
P222 | Do not allow contact with air. |
P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
P230 | Keep wetted |
P231 | Handle under inert gas. |
P232 | Protect from moisture. |
P233 | Keep container tightly closed. |
P234 | Keep only in original container. |
P235 | Keep cool |
P240 | Ground/bond container and receiving equipment. |
P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
P242 | Use only non-sparking tools. |
P243 | Take precautionary measures against static discharge. |
P244 | Keep reduction valves free from grease and oil. |
P250 | Do not subject to grinding/shock/friction. |
P251 | Pressurized container: Do not pierce or burn, even after use. |
P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
P262 | Do not get in eyes, on skin, or on clothing. |
P263 | Avoid contact during pregnancy/while nursing. |
P264 | Wash hands thoroughly after handling. |
P265 | Wash skin thouroughly after handling. |
P270 | Do not eat, drink or smoke when using this product. |
P271 | Use only outdoors or in a well-ventilated area. |
P272 | Contaminated work clothing should not be allowed out of the workplace. |
P273 | Avoid release to the environment. |
P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
P281 | Use personal protective equipment as required. |
P282 | Wear cold insulating gloves/face shield/eye protection. |
P283 | Wear fire/flame resistant/retardant clothing. |
P284 | Wear respiratory protection. |
P285 | In case of inadequate ventilation wear respiratory protection. |
P231 + P232 | Handle under inert gas. Protect from moisture. |
P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
Code | Phrase |
P301 | IF SWALLOWED: |
P304 | IF INHALED: |
P305 | IF IN EYES: |
P306 | IF ON CLOTHING: |
P307 | IF exposed: |
P308 | IF exposed or concerned: |
P309 | IF exposed or if you feel unwell: |
P310 | Immediately call a POISON CENTER or doctor/physician. |
P311 | Call a POISON CENTER or doctor/physician. |
P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
P313 | Get medical advice/attention. |
P314 | Get medical advice/attention if you feel unwell. |
P315 | Get immediate medical advice/attention. |
P320 | |
P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
P321 | |
P322 | |
P330 | Rinse mouth. |
P331 | Do NOT induce vomiting. |
P332 | IF SKIN irritation occurs: |
P333 | If skin irritation or rash occurs: |
P334 | Immerse in cool water/wrap n wet bandages. |
P335 | Brush off loose particles from skin. |
P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
P337 | If eye irritation persists: |
P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P342 | If experiencing respiratory symptoms: |
P350 | Gently wash with plenty of soap and water. |
P351 | Rinse cautiously with water for several minutes. |
P352 | Wash with plenty of soap and water. |
P353 | Rinse skin with water/shower. |
P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
P361 | Remove/Take off immediately all contaminated clothing. |
P362 | Take off contaminated clothing and wash before reuse. |
P363 | Wash contaminated clothing before reuse. |
P370 | In case of fire: |
P371 | In case of major fire and large quantities: |
P372 | Explosion risk in case of fire. |
P373 | DO NOT fight fire when fire reaches explosives. |
P374 | Fight fire with normal precautions from a reasonable distance. |
P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
P378 | |
P380 | Evacuate area. |
P381 | Eliminate all ignition sources if safe to do so. |
P390 | Absorb spillage to prevent material damage. |
P391 | Collect spillage. Hazardous to the aquatic environment |
P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
P370 + P376 | In case of fire: Stop leak if safe to Do so. |
P370 + P378 | In case of fire: |
P370 + P380 | In case of fire: Evacuate area. |
P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
Code | Phrase |
P401 | |
P402 | Store in a dry place. |
P403 | Store in a well-ventilated place. |
P404 | Store in a closed container. |
P405 | Store locked up. |
P406 | Store in corrosive resistant/ container with a resistant inner liner. |
P407 | Maintain air gap between stacks/pallets. |
P410 | Protect from sunlight. |
P411 | |
P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
P413 | |
P420 | Store away from other materials. |
P422 | |
P402 + P404 | Store in a dry place. Store in a closed container. |
P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
P403 + P235 | Store in a well-ventilated place. Keep cool. |
P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
P411 + P235 | Keep cool. |
Disposal | |
Code | Phrase |
P501 | Dispose of contents/container to ... |
P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
Code | Phrase |
H200 | Unstable explosive |
H201 | Explosive; mass explosion hazard |
H202 | Explosive; severe projection hazard |
H203 | Explosive; fire, blast or projection hazard |
H204 | Fire or projection hazard |
H205 | May mass explode in fire |
H220 | Extremely flammable gas |
H221 | Flammable gas |
H222 | Extremely flammable aerosol |
H223 | Flammable aerosol |
H224 | Extremely flammable liquid and vapour |
H225 | Highly flammable liquid and vapour |
H226 | Flammable liquid and vapour |
H227 | Combustible liquid |
H228 | Flammable solid |
H229 | Pressurized container: may burst if heated |
H230 | May react explosively even in the absence of air |
H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
H240 | Heating may cause an explosion |
H241 | Heating may cause a fire or explosion |
H242 | Heating may cause a fire |
H250 | Catches fire spontaneously if exposed to air |
H251 | Self-heating; may catch fire |
H252 | Self-heating in large quantities; may catch fire |
H260 | In contact with water releases flammable gases which may ignite spontaneously |
H261 | In contact with water releases flammable gas |
H270 | May cause or intensify fire; oxidizer |
H271 | May cause fire or explosion; strong oxidizer |
H272 | May intensify fire; oxidizer |
H280 | Contains gas under pressure; may explode if heated |
H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
H290 | May be corrosive to metals |
Health hazards | |
Code | Phrase |
H300 | Fatal if swallowed |
H301 | Toxic if swallowed |
H302 | Harmful if swallowed |
H303 | May be harmful if swallowed |
H304 | May be fatal if swallowed and enters airways |
H305 | May be harmful if swallowed and enters airways |
H310 | Fatal in contact with skin |
H311 | Toxic in contact with skin |
H312 | Harmful in contact with skin |
H313 | May be harmful in contact with skin |
H314 | Causes severe skin burns and eye damage |
H315 | Causes skin irritation |
H316 | Causes mild skin irritation |
H317 | May cause an allergic skin reaction |
H318 | Causes serious eye damage |
H319 | Causes serious eye irritation |
H320 | Causes eye irritation |
H330 | Fatal if inhaled |
H331 | Toxic if inhaled |
H332 | Harmful if inhaled |
H333 | May be harmful if inhaled |
H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
H335 | May cause respiratory irritation |
H336 | May cause drowsiness or dizziness |
H340 | May cause genetic defects |
H341 | Suspected of causing genetic defects |
H350 | May cause cancer |
H351 | Suspected of causing cancer |
H360 | May damage fertility or the unborn child |
H361 | Suspected of damaging fertility or the unborn child |
H361d | Suspected of damaging the unborn child |
H362 | May cause harm to breast-fed children |
H370 | Causes damage to organs |
H371 | May cause damage to organs |
H372 | Causes damage to organs through prolonged or repeated exposure |
H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
Code | Phrase |
H400 | Very toxic to aquatic life |
H401 | Toxic to aquatic life |
H402 | Harmful to aquatic life |
H410 | Very toxic to aquatic life with long-lasting effects |
H411 | Toxic to aquatic life with long-lasting effects |
H412 | Harmful to aquatic life with long-lasting effects |
H413 | May cause long-lasting harmful effects to aquatic life |
H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :